Pure Global
NCT05861466

Comparative Study Between IVI of Ranibizumab With and Without Prior ACP in Patients With DME Using OCT-A

Comparative Study Between Intravitreal Injection of Ranibizumab With and Without Prior Anterior Chamber Paracentesis in Patients With Diabetic Macular Oedema Using Optical Coherence Tomography Angiography [OCT-A]
Ain Shams University·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetic Macular Edema
Drug/Device/Intervention
intra-vitreal injection of Ranibizumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Ain Shams University
Location
Cairo, Egypt
Timeline & enrollment
Phase
Phase 4
Start date
Jan 01, 2023
End date
Apr 01, 2024
Enrollment
100 participants
Primary outcome

the acute change in angiographic parameters

Summary

The goal of this clinical trial is to to evaluate the changes in retinal microvasculature
 secondary to intra-ocular pressure changes post intra-vitreal injection in patients with
 diabetic macular oedema highlighting the effect of prior anterior chamber paracentesis on
 such changes if present .
 
 The main question[s]it aims to answer are:
 
 •[is there any effect of post intra-vitreal injection IOP spikes on retinal
 microvasculature?] •[is there any effect of Prior Anterior Chamber Paracentesis?]
 Participants in group A will be subjected to an identified approved treatment( intra-vitreal
 injection)& Participants in group B will be subjected to a prior ACP with the intra-vitreal
 injection . ]

ICD-10 classifications
Diabetic retinopathyOther specified diabetes mellitus with ophthalmic complicationsUnspecified diabetes mellitus with ophthalmic complicationsDiabetic cataractType 2 diabetes mellitus with ophthalmic complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05861466
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05861466 through Pure Global AI's free database. This Phase 4 trial is sponsored by Ain Shams University and is currently Recruiting. The study focuses on Diabetic Macular Edema. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.